SHORTS WILL COVER BEFORE THE CLOSE! ARNA will likely be bought out, more then likely after QNEXA gets a 50/50 change of approval. Even if QNEXA gets approval there will be several limitations to the drug, which with cause ARANA to spike. If QNEXA gets denied approval ARNA spikes to at least $20.00, and becomes the only FDA approved obesity drug on the market. This would be a big pharma buyout bidding war! This is my opinion only.
Market Data 
Markets 
AI
